Observed and Normative Discount Functions in Addiction and other Diseases

The aim of this paper is to find a suitable discount function able to describe the progression of a certain addiction or disease under treatment as a discounting process. In effect, a certain indicator related to a disease decays over time in a manner which is mathematically similar to the way in wh...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 8; p. 416
Main Authors Cruz Rambaud, Salvador, Muñoz Torrecillas, María J., Takahashi, Taiki
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 29.06.2017
Subjects
Online AccessGet full text
ISSN1663-9812
1663-9812
DOI10.3389/fphar.2017.00416

Cover

More Information
Summary:The aim of this paper is to find a suitable discount function able to describe the progression of a certain addiction or disease under treatment as a discounting process. In effect, a certain indicator related to a disease decays over time in a manner which is mathematically similar to the way in which discounting has been modeled. We analyze the discount functions observed in experiments which study addictive and other problematic behaviors as well as some alternative hyperbola-like discount functions in order to fit the patience exhibited by the subject after receiving the treatment. Additionally, it has been experimentally found that people with addiction display high rates of discount (impatience) and preference reversals (dynamic inconsistency). This excessive discounting must be correctly modeled by a suitable discount function, otherwise, it can become a trans-disease process underlying addiction and other disorders. The (generalized) exponentiated hyperbolic discount function is proposed to describe the progression of a disease with respect to the treatment, since it maintains the property of inconsistency by exhibiting a decreasing discount rate after an initial period in which the opposite occurs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Antonio Maturo, Università degli Studi “G. d'Annunzio” Chieti - Pescara, Italy; Carlos Rodriguez Palmero, University of Valladolid, Spain
This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology
Edited by: Mihajlo Jakovljevic, University of Kragujevac, Serbia
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2017.00416